June 21, 2024
United Kingdom Ulcerative Colitis Market

The United Kingdom Ulcerative Colitis Market is trending by growing biologics adoption

Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers in the colon and rectum. The disease affects the innermost lining of the large intestine and rectum resulting in symptoms like abdominal pain, rectal bleeding and frequent bowel movements. Traditional therapeutic drugs like aminosalicylates, corticosteroids and immunomodulators are used to induce and maintain remission in ulcerative colitis patients. However, growing preference for more targeted biologics therapies for improved treatment outcomes and lesser side effects is driving significant growth.

The Global United Kingdom Ulcerative Colitis Market Size is estimated to be valued at US$ 421.3 Mn in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast period 2024-2031.

Growing awareness and diagnosis rates have increased the demand for high-efficacy drugs for UC management. Pharmaceutical companies are investing in R&D to develop novel biologics with improved safety profiles to expand market access.

Key Takeaways

Key players operating in the United Kingdom Ulcerative Colitis are AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson. AbbVie leads the UK market with its blockbuster drug Humira.

Rising disease prevalence coupled with growing risk factors like smoking, obesity and lack of physical activity have boosted the demand for ulcerative colitis drugs in the UK. As per Crohn’s & Colitis UK, over 146,000 people in the UK suffer from ulcerative colitis currently.

Pharmaceutical companies are expanding their operations in Europe to improve access to biologics for ulcerative colitis patients. In 2021, Takeda Pharmaceutical acquired several assets from Pfizer Inc. to become a top 10 player in gastroenterology and strengthen its presence in the UK market.

Market key trends

Growing adoption of biosimilars is one of the key trends in the UK ulcerative colitis market. The approval and launch of low-cost biosimilar versions of drugs like infliximab has improved treatment affordability and compliance rates. As per estimates, biosimilars could save the National Health Service (NHS) £200 million annually.

Increased collaborations between biotechs and large pharma to develop novel mechanisms of action is another major trend. For instance, Morphic Therapeutic and Pfizer are evaluating MORF-057, an oral small molecule targeting the αvß8 integrin, for UC treatment. If approved, it will be a first-in-class oral therapy for UC.

Porter’s Analysis

Threat Of New Entrants: High cost of establishing biologics production facilities and high regulatory barriers reduce the threat.

Bargaining Power Of Buyers: Large pharmacy benefit managers can negotiate lower drug prices with manufacturers.

Bargaining Power Of Suppliers: Established drug manufacturers in this space hold more bargaining power over suppliers of raw materials and components.

Threat Of New Substitutes: Approval of new drugs and treatment bring substitutes which impacts market.

Competitive Rivalry: Intense as leading players compete to gain market share through differentiated products and services.

Geographical Regions

North America holds the major market share in terms of value due to rise in research activities, growing healthcare expenditure, and increasing prevalence of ulcerative colitis. The United States accounts for the largest share in North America followed by Canada.

Asia Pacific is expected to grow at the highest CAGR during the forecast period attributed to rise in healthcare expenditure, large patient pool, and increase in awareness about ulcerative colitis. Rapid economic development in emerging countries such as China and India with large population also contributes to lucrative opportunities.

What Are The Key Data Covered In This United Kingdom Ulcerative Colitis Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the United Kingdom Ulcerative Colitis Market’s growth between 2024 and 2031.

:- Accurate calculation of the size of the United Kingdom Ulcerative Colitis Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- United Kingdom Ulcerative Colitis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of United Kingdom Ulcerative Colitis Market vendors

FAQ’S

Q.1 What are the main factors influencing the United Kingdom Ulcerative Colitis market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top United Kingdom Ulcerative Colitis Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the United Kingdom Ulcerative Colitis market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it